{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:45:12Z","timestamp":1787589912797,"version":"build-2736575974"},"reference-count":28,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"unspecified","delay-in-days":90,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2025,9,6]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mavacamten has revolutionised the treatment of hypertrophic obstructive cardiomyopathy (HOCM) but requires frequent follow-up. Routine ECG may offer an accessible tool to indicate response to therapy. This study evaluates ECG-based indices of left ventricular hypertrophy (LVH) in patients with HOCM receiving mavacamten therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, after screening of 62 consecutive patients with HOCM treated at a German tertiary referral centre from August 2023 to February 2025, 31 patients (42% female, mean age 61\u00b112 years) were included. During the first 12 weeks of myosin inhibitor treatment, echocardiographic parameters, laboratory values, symptoms and ECG LVH indices were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mavacamten reduced the mean left ventricular outflow tract obstruction (LVOTO) during Valsalva from 103\u2009mm Hg (73\u2013145) to 32\u2009mm Hg (19\u201360), (p&lt;0.001). All ECG LVH indices significantly decreased with treatment (Sokolow-Lyon Index: 2.56\u00b10.97\u2009mm vs 2.04\u00b10.75\u2009mm, p&lt;0.001; Cornell criteria: 1.23\u2009mm (0.92\u20132.21) vs 0.92\u2009mm (0.75\u20131.75), p=0.001; Peguero-Lo Presti criteria: 2.39\u2009mm (1.62\u20133.22) vs 1.61\u2009mm (1.12\u20132.01), p&lt;0.001; all pre vs post mavacamten). Notably, an increase in the Sokolow-Lyon Index and Peguero-Lo Presti criteria correlated with worsening LVOTO (area under the curve 0.72 and 0.88, respectively). Sensitivity and specificity of ECG LVH indices for detecting LVOTO progression during therapy were 100% and 88.6%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A combinatory ECG-based approach using the Sokolow-Lyon Index and Peguero-Lo Presti criteria may serve as an accessible tool for monitoring LVOTO progression in patients with HOCM on mavacamten. Prospective validation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2025-003611","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:20:14Z","timestamp":1759144814000},"page":"e003611","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["ECG markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy"],"prefix":"10.1136","volume":"12","author":[{"given":"Florian","family":"Buehning","sequence":"first","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Lerchner","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Vogel","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Kolk","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Vogel","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Seuthe","sequence":"additional","affiliation":[{"name":"Department III of Internal Medicine, Heart Center, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ferdinandy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary"},{"name":"Center for Pharmacology and Drug Research and Development, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Abbas","family":"Mahabadi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6122-5652","authenticated-orcid":false,"given":"Lars","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2026010701111775000_12.2.e003611.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.068"},{"key":"2026010701111775000_12.2.e003611.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311059"},{"key":"2026010701111775000_12.2.e003611.3","doi-asserted-by":"crossref","DOI":"10.3390\/genes16010074","article-title":"Hypertrophic Cardiomyopathy: New Clinical and Therapeutic Perspectives of an \u201cOld\u201d Genetic Myocardial Disease","volume":"16","author":"Calore","year":"2025","journal-title":"Genes (Basel)"},{"key":"2026010701111775000_12.2.e003611.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.4.785"},{"key":"2026010701111775000_12.2.e003611.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.05.009"},{"key":"2026010701111775000_12.2.e003611.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"2026010701111775000_12.2.e003611.7","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026010701111775000_12.2.e003611.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101210","article-title":"Atrial Fibrillation in Hypertrophic Cardiomyopathy","volume":"3","author":"Weissler-Snir","year":"2024","journal-title":"JACC Adv"},{"key":"2026010701111775000_12.2.e003611.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01727-2"},{"key":"2026010701111775000_12.2.e003611.10","doi-asserted-by":"publisher","DOI":"10.1161\/hc4601.097997"},{"key":"2026010701111775000_12.2.e003611.11","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-304276"},{"key":"2026010701111775000_12.2.e003611.12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/ehjci\/jeaa423","article-title":"Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study","volume":"22","author":"Greulich","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026010701111775000_12.2.e003611.13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009873","article-title":"Evolving Epidemiology of Hypertrophic Cardiomyopathy: Shifting the Focus From Instant to Lifetime Risk Awareness","volume":"15","author":"Canepa","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010701111775000_12.2.e003611.14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jacc.2023.10.032","article-title":"Sudden Cardiac Death in Young Athletes: JACC State-of-the-Art Review","volume":"83","author":"Finocchiaro","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026010701111775000_12.2.e003611.15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.804617"},{"key":"2026010701111775000_12.2.e003611.16","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7622","article-title":"Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients","volume":"9","author":"Nag","year":"2023","journal-title":"Sci Adv"},{"key":"2026010701111775000_12.2.e003611.17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.17925\/HI.2022.16.2.91","article-title":"Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy","volume":"16","author":"Reyes","year":"2022","journal-title":"Heart Int"},{"key":"2026010701111775000_12.2.e003611.18","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"The Lancet"},{"key":"2026010701111775000_12.2.e003611.19","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"key":"2026010701111775000_12.2.e003611.20","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012545","article-title":"Stop Dreaming: Mavacamten REMS Data Are Here","volume":"18","author":"Masri","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026010701111775000_12.2.e003611.21","unstructured":"Food and drug administration updates CAMZYOS (mavacamten) label to reduce echocardiography monitoring requirements and contraindications. 2025. Available: https:\/\/news.bms.com\/news\/details\/2025\/U-S--Food-and-Drug-Administration-Updates-CAMZYOS-mavacamten-Label-to-Reduce-Echocardiography-Monitoring-Requirements-and-Contraindications\/default.aspx"},{"key":"2026010701111775000_12.2.e003611.22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.hrthm.2019.07.019","article-title":"The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy","volume":"17","author":"Finocchiaro","year":"2020","journal-title":"Heart Rhythm"},{"key":"2026010701111775000_12.2.e003611.23","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2024.03.1495","article-title":"PO-05-054 DYNAMIC IMPACT OF MAVACAMTEN ON ECG PATTERNS OF LEFT VENTRICULAR HYPERTROPHY WITH LEFT VENTRICULAR STRAIN","volume":"21","author":"Austin","year":"2024","journal-title":"Heart Rhythm"},{"key":"2026010701111775000_12.2.e003611.24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjcard.2024.11.028","article-title":"A Multicenter Evaluation of the Impact of Therapies on Deep Learning-Based Electrocardiographic Hypertrophic Cardiomyopathy Markers","volume":"237","author":"Dhingra","year":"2025","journal-title":"Am J Cardiol"},{"key":"2026010701111775000_12.2.e003611.25","doi-asserted-by":"crossref","DOI":"10.31083\/j.rcm2309319","article-title":"Performance of the Newly Proposed Peguero-Lo Presti Criterion in Adults with Hypertrophic Cardiomyopathy","volume":"23","author":"Cao","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"2026010701111775000_12.2.e003611.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.09.1381"},{"key":"2026010701111775000_12.2.e003611.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052359"},{"key":"2026010701111775000_12.2.e003611.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht439"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2025-003611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:11:31Z","timestamp":1767777091000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2025-003611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/openhrt-2025-003611"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2025-003611","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}